Roche TCRC, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$106.0M
Doctors Paid
51
Transactions
6,419
2024 Total
$15.4M
Payment Breakdown by Category
Research$105.8M (99.8%)
Royalty/License$87,784 (0.1%)
Travel$67,602 (0.1%)
Consulting$64,328 (0.1%)
Food & Beverage$12,229 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $105.8M | 6,266 | 99.8% |
| Royalty or License | $87,784 | 16 | 0.1% |
| Travel and Lodging | $67,602 | 79 | 0.1% |
| Consulting Fee | $64,328 | 11 | 0.1% |
| Food and Beverage | $12,229 | 45 | 0.0% |
| Grant | $4,450 | 2 | 0.0% |
Payments by Type
Research
$105.8M
6,266 transactions
General
$236,393
153 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | $18.9M | 0 | 1,351 |
| PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | $14.4M | 0 | 865 |
| Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME | $8.4M | 0 | 328 |
| THE EFFECT OF 24WEEK TREATMENT WITH BASMISANIL ON COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA | $7.7M | 0 | 856 |
| Phase II study in early stage Parkinson s Disease Patients | $7.6M | 1 | 749 |
| COMBO SAD MAD TO ASSESS THE SAFETY AND TOLERABILITY OF MCP IN HEALTHY VOLUNTEERS | $4.0M | 0 | 47 |
| PROOF OF MECHANISM STUDY COMPARATIVE STUDY OF TAAR1 4 ADD ON VS PLACEBO ADD ON IN SCHIZOPHRENIC PTS | $3.4M | 0 | 83 |
| ORAL TREATMENT OF NPDR | $3.1M | 0 | 377 |
| BRAIN SHUTTLE GANT SAD STUDY | $2.9M | 0 | 28 |
| FOOD EFFECT STUDY WITH RALMITARONT 2 | $2.8M | 0 | 28 |
| RO7200220 FOR DIABETICA AND UVEITICA MACULAR EDEMA | $2.6M | 0 | 112 |
| RO7200394 FOR NAMD | $2.1M | 0 | 182 |
| PHASE 1 BRONCHOALVEOLAR LAVAGE STUDY IN HEALTHY VOLUNTEER 3 | $1.7M | 0 | 8 |
| A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | $1.7M | 0 | 155 |
| ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | $1.6M | 0 | 155 |
| DDI STUDY WITH RISPERIDONE | $1.5M | 0 | 8 |
| MAD HV STUDY OF RO7079901 GIVEN ALONE OR WITH MEROPENEM | $1.4M | 0 | 26 |
| Oral Treatment of NPDR | $1.4M | 0 | 166 |
| HLA G TCB Entry into Human study | $1.3M | 0 | 14 |
| Phase 1 PK Study in Renal Impairment population 2 | $1.2M | 0 | 68 |
| V1A3 DDI 1 | $1.1M | 0 | 16 |
| RELATIVE BIOAVAILABILITY STUDY | $1.0M | 0 | 14 |
| V1A 2 IN PEDIATRIC AUTISM | $943,535 | 0 | 127 |
| PHASE 2 STUDY OF ANTI IL6 MAB WITH RBZ IN COMBINATION IN PATIENTS WITH DME | $933,112 | 0 | 38 |
| PK ETHNICITY BRIDGING STUDY | $905,641 | 0 | 24 |
| PROOF OF MECHANISM STUDY COMPARATIVE STUDY OF TAAR1 4 VS PLACEBO IN SCHIZOPHRENIC PTS | $768,997 | 0 | 4 |
| RO7200220 FOR DIABETIC MACULAR EDEMA | $761,277 | 0 | 85 |
| PRIMARY OPEN ANGLE GLAUCOMA POAG OR OCULAR HYPERTENSION OHT | $742,251 | 0 | 35 |
| GYM329 ANTI LATENT MYOSTATIN FIM SAD IN HVS | $723,480 | 0 | 14 |
| Antibiotics MCP patient PK study | $559,422 | 0 | 18 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Ophthalmology | $32,152 | 11 | $2,923 |
| Medical Oncology | $31,042 | 2 | $15,521 |
| Neurology | $14,934 | 11 | $1,358 |
| Student in an Organized Health Care Education/Training Program | $13,660 | 1 | $13,660 |
| Psychiatry | $12,806 | 3 | $4,269 |
| Hematology & Oncology | $12,640 | 4 | $3,160 |
| Retina Specialist | $12,583 | 9 | $1,398 |
| Internal Medicine | $6,045 | 2 | $3,022 |
| Infectious Disease | $4,019 | 2 | $2,009 |
| Optometrist | $1,514 | 1 | $1,514 |
| Specialist | $1,398 | 1 | $1,398 |
| Rheumatology | $566.00 | 1 | $566.00 |
| Hematology | $95.31 | 2 | $47.66 |
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Dr. David Payne, M.d, M.D | Specialist | New York, NY | $1,398 | $0 |
| Ryan Constantine, M.d., Phd, M.D., PHD | Retina Specialist | Erie, PA | $1,391 | $0 |
| Dr. Venkatachalam Veerappan, M.d, M.D | Neurology | Greenville, SC | $1,383 | $0 |
| Dr. Jorge Calzada, M.d, M.D | Retina Specialist | Southaven, MS | $1,381 | $0 |
| Dr. Matthew Boyce, M.d, M.D | Neurology | Richmond, VA | $1,378 | $0 |
| Srinath Kadimi, M.d, M.D | Neurology | Fairfield, CT | $1,363 | $0 |
| Mr. Harit Bhatt, M.d, M.D | Retina Specialist | Oak Forest, IL | $1,332 | $0 |
| Vrinda Hershberger, Md, MD | Retina Specialist | Melbourne, FL | $1,330 | $0 |
| Dr. Andres Emanuelli Anzalotta, M.d, M.D | Ophthalmology | Arecibo, PR | $1,273 | $0 |
| Irene Richard, Md, MD | Neurology | Rochester, NY | $1,237 | $0 |
| Dr. Oren Levy, M.d, M.D | Neurology | New York, NY | $1,148 | $0 |
| James Peace, M.d. Inc, M.D. INC | Retina Specialist | Inglewood, CA | $1,027 | $0 |
| David Eichenbaum, M.d, M.D | Retina Specialist | St Petersburg, FL | $842.11 | $0 |
| Unknown Provider | — | — | $831.01 | $0 |
| Carl Danzig, M.d, M.D | Ophthalmology | Bonita Springs, FL | $709.44 | $0 |
| Robert Coleman, Md, MD | Neurology | Grand Rapids, MI | $566.00 | $0 |
| Elaine Adams, Md, MD | Rheumatology | Maywood, IL | $566.00 | $0 |
| Dr. Ronald Hoffman, M.d, M.D | Hematology & Oncology | New York, NY | $461.00 | $0 |
| Dr. Stuart Isaacson, Md, MD | Neurology | Boca Raton, FL | $126.00 | $0 |
| Dr. Andrew Pecora, Md, MD | Hematology | Hackensack, NJ | $73.37 | $0 |
| Douglas Day, M.d, M.D | Ophthalmology | Atlanta, GA | $31.00 | $0 |
| Hearn Cho, Md, MD | Hematology | New York, NY | $21.94 | $0 |
| Dr. Ajai Chari, M.d, M.D | Hematology & Oncology | New York, NY | $21.94 | $0 |
| Mr. Samir Parekh, M.d, M.D | Medical Oncology | New York, NY | $21.94 | $0 |
| Deepu Madduri, Md, MD | Internal Medicine | Stanford, CA | $21.94 | $0 |
Ad
Top Products
- Non-Covered Product $36.8M
- Lucentis $23.2M
Payment Categories
- Food & Beverage $12,229
- Consulting $64,328
- Travel & Lodging $67,602
- Research $105.8M
- Royalties $87,784
About Roche TCRC, Inc.
Roche TCRC, Inc. has made $106.0M in payments to 51 healthcare providers, recorded across 6,419 transactions in the CMS Open Payments database. In 2024, the company paid $15.4M. The top product by payment volume is Non-Covered Product ($36.8M).
Payments were distributed across 13 medical specialties. The top specialty by payment amount is Ophthalmology ($32,152 to 11 doctors).
Payment categories include: Food & Beverage ($12,229), Consulting ($64,328), Research ($105.8M), Travel & Lodging ($67,602), Royalties ($87,784).